Chair: Henry Rodriguez, USA
Co-chair: Yu-Ju Chen, Taiwan
Speaker: Matthew Ellis, USA - New Prospects for Killing ER+ Breast Cancer (Micro-scale Proteogenomics)
Speaker: Amanda Paulovich, USA - Building New Clinical Solutions for Precision Oncology via Proteogenomics
Speaker: Albert Sickmann, Germany - Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data
Ever since the announcement of the Precision Medicine Initiative, there have been increasing efforts to identify and understand the basis of cancer using high-throughput technologies and the development of specialized treatments for specific subtypes of cancer, based on molecular evidence. Clinical proteogenomics is an exciting opportunity to complement the gene testing-centric clinical community for precision medicine. However, translating proteomic measurements to real-world patient care requires synergy of multiple requirements: meaningful and actionable molecular characterization, clinical and analytical validation, defining diagnosis values, and meeting regulatory compliance.
This HUPO session showcases clinical researchers discussing their stories and strategies to move proteomics towards better patient/clinical care. During this interactive broadcast, learn about the insight of three stories:
- Microscaled proteogenomics technology for predicting response of triple negative breast cancer
- Development of robust targeted platforms for clinical laboratory tests, drug development, and clinical trials
- Proteogenomics/Proteomics: Complementing Precision Medicine with Phenotypic Data
Dr. Henry Rodriguez is the Founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute (NCI), National Institutes of Health (NIH). Dr. Rodriguez is also a member of NCI’s Senior Leadership. A cell and molecular biologist with a background in business, Dr. Rodriguez’s biomedical research has focused on mechanisms of cancer in basic and clinical science, and the development of measurement science, standards, and technology.
Dr. Rodriguez earned his A.A. in biology from Miami Dade College, B.S. in biology/chemistry and M.S. in biology from Florida International University, Ph.D. in cell and molecular biology from Boston University, and M.B.A. in finance and management from Johns Hopkins University Carey Business School. Fellowships were conducted at the Scripps Research Institute and City of Hope Comprehensive Cancer Center. Dr. Rodriguez has authored more than 147 original research papers, including co-editing a book on oxidative stress and aging.
Yu-Ju Chen received Ph.D. degree in physical chemistry from Iowa State University. After postdoctoral work at Ames Laboratory, USA and National Tsing Hua University, Dr. Chen joined the Institute of Chemistry of Academia Sinica and is currently a Distinguished Research Fellow. She is also the President of Human Proteome Organization, past Vice President of Asia Oceana Human Proteome Organization, past President of Taiwan Proteomics Society and Taiwan Society for Mass Spectrometry. Dr. Chen is the Associate Editor of Analytical Chemistry and editorial board member of the Proteomics and Scientific Report.
Towards comprehensive profiling of human proteome, Dr. Chen’s interests focus on integrating nanomaterials, advanced mass spectrometry and bioinformatics to develop advanced proteomics technologies for quantitative membrane proteomics and protein post-translational modification. She also established extensive domestic and international collaboration network to apply proteomic methodologies to delineate the disease mechanism in cancer biology.
To view this presentation, please login with your HUPO Connect Webinar Series login credentials. If you do not have an account or access to this presentation, please click here to register an account.